Bando H - Search Results

1

Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers.

Ogasawara N, Bando H, Kawamoto Y, Yoshino T, Tsuchihara K, Ohtsu A, Esumi H. Ogasawara N, et al. Among authors: bando h. Jpn J Clin Oncol. 2011 Jan;41(1):52-6. doi: 10.1093/jjco/hyq151. Epub 2010 Aug 9. Jpn J Clin Oncol. 2011. PMID: 20696815

2

[Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].

Yoda Y, Yoshino T, Kadowaki S, Bando H, Okano S, Fukushima H, Fuse N, Tahara M, Doi T, Ohtsu A. Yoda Y, et al. Among authors: bando h. Gan To Kagaku Ryoho. 2009 Jun;36(6):1003-6. Gan To Kagaku Ryoho. 2009. PMID: 19542725 Japanese.

3

A laterally-spreading tumor in a colonic interposition treated by endoscopic submucosal dissection.

Bando H, Ikematsu H, Fu KI, Oono Y, Kojima T, Minashi K, Yano T, Matsuda T, Saito Y, Kaneko K, Ohtsu A. Bando H, et al. World J Gastroenterol. 2010 Jan 21;16(3):392-4. doi: 10.3748/wjg.v16.i3.392. World J Gastroenterol. 2010. PMID: 20082488 Free PMC article. Review.

4

Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing.

Bando H, Tsuchihara K, Yoshino T, Kojima M, Ogasawara N, Fukushima H, Ochiai A, Ohtsu A, Esumi H. Bando H, et al. Jpn J Clin Oncol. 2011 Feb;41(2):239-44. doi: 10.1093/jjco/hyq216. Epub 2010 Nov 26. Jpn J Clin Oncol. 2011. PMID: 21113056

5

Early clinical outcomes of anal squamous cell carcinoma treated with concurrent chemoradiotherapy with 5-Fluorouracil plus mitomycin C in Japanese patients: experience at a single institution.

Satake H, Yoshino T, Sasaki T, Bando H, Yoda Y, Ikematsu H, Kojima T, Fuse N, Zenda S, Doi T, Kaneko K, Ohtsu A. Satake H, et al. Among authors: bando h. Jpn J Clin Oncol. 2012 Sep;42(9):861-4. doi: 10.1093/jjco/hys093. Epub 2012 Jun 19. Jpn J Clin Oncol. 2012. PMID: 22717459

6

Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.

Bando H, Yoshino T, Yuki S, Shinozaki E, Nishina T, Kadowaki S, Yamazaki K, Kajiura S, Tsuchihara K, Fujii S, Yamanaka T, Ohtsu A. Bando H, et al. Jpn J Clin Oncol. 2012 Dec;42(12):1146-51. doi: 10.1093/jjco/hys160. Epub 2012 Oct 15. Jpn J Clin Oncol. 2012. PMID: 23071293

7

[Predictive biomarkers for anti-EGFR antibodies].

Bando H, Yoshino T. Bando H, et al. Gan To Kagaku Ryoho. 2012 Nov;39(11):1618-25. Gan To Kagaku Ryoho. 2012. PMID: 23152013 Review. Japanese.

8

[Chemotherapy with molecular targeting agents for colorectal cancer].

Bando H, Ohtsu A. Bando H, et al. Nihon Rinsho. 2012 Nov;70 Suppl 8:468-74. Nihon Rinsho. 2012. PMID: 23513885 Japanese. No abstract available.

9

Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.

Bando H, Yoshino T, Shinozaki E, Nishina T, Yamazaki K, Yamaguchi K, Yuki S, Kajiura S, Fujii S, Yamanaka T, Tsuchihara K, Ohtsu A. Bando H, et al. BMC Cancer. 2013 Sep 3;13:405. doi: 10.1186/1471-2407-13-405. BMC Cancer. 2013. PMID: 24006859 Free PMC article.

10

Clinical outcomes in 66 patients with advanced gastric cancer treated in phase I trials: the NCCHE experience.

Kawazoe A, Shitara K, Fukuoka S, Noguchi M, Kuboki Y, Bando H, Okamoto W, Kojima T, Fuse N, Yoshino T, Ohtsu A, Doi T. Kawazoe A, et al. Among authors: bando h. Invest New Drugs. 2015 Jun;33(3):664-70. doi: 10.1007/s10637-015-0231-9. Epub 2015 Mar 15. Invest New Drugs. 2015. PMID: 25773493

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

733 results

Search Page

Filters